SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: betty moyers who wrote (18835)2/17/1999 6:27:00 PM
From: DaiS  Read Replies (3) of 23519
 
Betty,

I had not seen before the total 1998 Astra revenue for muse.

So we have for Astra revenue in US dollars:
Q1+Q2 = 3.785M (communication to DaiS from Astra)
Q1+Q2+Q3 = 7.696 M (communication to DaiS from Astra)
Q1+Q2+Q3+Q4 = 10.850 M (from Astra web site)

Gives:
Q3 revenue = 3.911 M
Q4 revenue = 3.154 M

Decline in specification Q3 to Q4 = 19.4%

It came from several sources that for UK alone quarterly revenue was at the level 2.5M dollars. Now for revenue 2.5/3.154 is 79%, and for population UK/(UK+Swe+Swi) is 78%.

Muse launched UK, February and Sweden and Switzerland, May(?).

Viagra launched in EU in September. I think it is fair to assume that muse has faced full viagra competition during Q4 in the above countries. We have also been told that in UK viagra hit hard initially but then muse recovered to original levels. Thus the 19.4% would represent a larger decline caused by the initial viagra hit.

DaiS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News